| Literature DB >> 18298956 |
Cédric Langhi1, Cédric Le May, Sanae Kourimate, Sandrine Caron, Bart Staels, Michel Krempf, Philippe Costet, Bertrand Cariou.
Abstract
The purpose of this study was to determine whether bile acids (BAs) modulate hepatic pro-protein convertase subtilisin/kexin 9 (PCSK9) gene expression. Immortalized human hepatocytes were treated with various BAs. Chenodeoxycholic acid (CDCA) treatment specifically decreased both PCSK9 mRNA and protein contents. Moreover, activation of the BA-activated farnesoid X receptor (FXR) by its synthetic specific agonist GW4064 also decreased PCSK9 expression. Of functional relevance, coadministration of CDCA counteracted the statin-induced PCSK9 expression, leading to a potentiation of LDL receptor activity. This study suggests that a transcriptional repression of PCSK9 by CDCA or FXR agonists may potentiate the hypolipidemic effect of statins.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18298956 DOI： 10.1016/j.febslet.2008.02.038
Source DB: PubMed Journal: FEBS Lett ISSN： 0014-5793 Impact factor: 4.124